|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|5665889||1407776||2017||3 صفحه PDF||سفارش دهید||دانلود کنید|
- Emerging therapies including CAR T-cells can present false-positive HIV NAT results.
- Guidelines for HIV testing are needed for lentiviral transduced T-cells protocols.
- As cancer-immunotherapy progresses, clinicians to be observant of new adverse events.
Advancements in immunotherapy have opened a new era in oncology, to include genetic modification of human T-cells to express a chimeric antigen receptor (CAR) that enables targeted tumor recognition (Kochenderfer et al., 2015; Lee et al., 2015; Maus and Levine 2016; Rosenberg et al., 2008). Herein, we report a false-positive HIV testing in a patient who had undergone CAR T-cell therapy created with a lentiviral vector.
Journal: Diagnostic Microbiology and Infectious Disease - Volume 88, Issue 4, August 2017, Pages 305-307